Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Carcinoma, Hepatocellular 26Small Cell Lung Carcinoma 17Lung Neoplasms 15Neoplasms 13Breast Neoplasms 8Colorectal Neoplasms 7Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Melanoma 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Carcinoma, Transitional Cell 5Prostatic Neoplasms 4Glioblastoma 4Stomach Neoplasms 3Solid Tumors 3Sarcoma, Alveolar Soft Part 3Sarcoma 3Liver Neoplasms 3Extensive Stage Lung Small Cell Carcinoma 3Carcinoma 3Treatment-Refractory Solid Tumors 2Small Cell Lung Cancer Extensive Stage 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Nasopharyngeal Carcinoma 2

Interventions

pertuzumab 5Trastuzumab 5Docetaxel 3tucatinib 2pyrotinib 1atezolizumab 1Paclitaxel 1Neoadjuvant Therapy 1Injections 1Genetic Testing 1Carboplatin 1Capecitabine 1Blood Specimen Collection 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × atezolizumab × 90 days × Clear all
NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
16 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡